Changing perceptions in osteoporosis Commentary: Bone density can be used to assess fracture risk
- 27 March 1999
- Vol. 318 (7187), 862-865
- https://doi.org/10.1136/bmj.318.7187.862
Abstract
# Changing perceptions in osteoporosis {#article-title-2} A recent meta-analysis of 11 separate study populations and over 2000 fractures concluded that bone mineral density “cannot identify individuals who will have a fracture.”1 So why do we measure it? The question is worth asking when the number of dual energy x ray absorptiometry machines installed in the United Kingdom exceeds 130 (National Osteoporosis Society, personal communication), and the number of Medline citations incorporating the term dual energy x ray absorptiometry has grown from 26 in 1988 to 464 in 1997. The concept of “fracture threshold” has led to the recommendation that preventive treatment be given to women once their bone density lies (arbitrarily) more than 1 SD below the mean for premenopausal women—a state of osteopenia, according to the WHO definition. But should we be managing osteoporosis by numbers? #### Summary points Bone densitometry cannot identify people who will sustain osteoporotic fracture Bone density changes little with antiresorptive treatment (hormone replacement therapy and bisphosphonate drugs), whereas bone turnover falls dramatically Bone turnover may be the responsive element in treatments to prevent osteoporotic fracture Antiresorptive treatments prevent fracture, regardless of whether they are given at the menopause or decades later Since frequency of impact, which rises exponentially with age, is the main risk factor for fracture, treatment should be focused on infirm older people, irrespective of their bone density Bone comprises a matrix framework on which mineral is deposited. Osteoporosis is caused by the disintegration of the matrix, and osteomalacia by a failure to mineralise it. When mineralised matrix disintegrates, calcium is inevitably lost. The negative calcium balance observed with matrix loss gave rise to erroneous beliefs that the calcium requirements of postmenopausal women were higher than those of premenopausal women and that osteoporosis could be prevented by calcium supplementation.2 Calcium is crucial during the development of bone, but it …Keywords
This publication has 20 references indexed in Scilit:
- Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosisThe Lancet, 1997
- Bone density and risk of hip fracture in men and women: cross sectional analysisBMJ, 1997
- The value of biochemical markers of bone turnover in osteoporosis.1997
- Calcium Intake and Fracture Risk: Results from the Study of Osteoporotic FracturesAmerican Journal of Epidemiology, 1997
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracturesBMJ, 1996
- Drug therapy for vertebral fractures in osteoporosis: Evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacyBone, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- ABC of Rheumatology: OSTEOPOROSISBMJ, 1995
- Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.Journal of Clinical Endocrinology & Metabolism, 1994